10th week of 2022 patent applcation highlights part 26 |
Patent application number | Title | Published |
20220073582 | PEPTIDE IMMUNOGENS TARGETING CALCITONIN GENE-RELATED PEPTIDE (CGRP) AND FORMULATIONS THEREOF FOR PREVENTION AND TREATMENT OF MIGRAINE - The present disclosure is directed to peptide immunogen constructs targeting portions of Calcitonin Gene-Related Peptide (CGRP), compositions containing the constructs, antibodies elicited by the constructs, and methods for making and using the constructs and compositions thereof. The disclosed peptide immunogen constructs have more than about 30 amino acids and contain (a) a B cell epitope having about more than about 7 contiguous amino acid residues from the CGRP receptor binding or activation regions of the full-length CGRP protein; (b) a heterologous Th epitope; and (c) an optional heterologous spacer. The disclosed CGRP peptide immunogen constructs stimulate the generation of highly specific antibodies directed CGRP for the prevention and/or treatment of migraine. | 2022-03-10 |
20220073583 | ACYLATED GLUCAGON ANALOGUES - The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon. | 2022-03-10 |
20220073584 | RELAXIN FUSION POLYPEPTIDES AND USES THEREOF - The present invention relates to Relaxin fusion polypeptides, in particular to Relaxin 2 fusion polypeptides and uses thereof. Thus, the invention provides Relaxin fusion polypeptides, nucleic acid molecules, vectors, host cells, pharmaceutical compositions and kits comprising the same and uses of the same including methods of treatment. The polypeptides and compositions of the invention may be useful, in particular, in the treatment of cardiovascular diseases, for example for the treatment of heart failure. | 2022-03-10 |
20220073585 | CHIMERIC ANTIGEN RECEPTOR MEMORY-LIKE (CARML) NK CELLS AND METHODS OF MAKING AND USING SAME - Among the various aspects of the present disclosure is the provision of a chimeric antigen receptor memory-like (CARML) NK cell and methods of making and using same. | 2022-03-10 |
20220073586 | PD-1 POLYPEPTIDE VARIANTS - Provided are PD-1 polypeptide variants including an extracellular domain that binds specifically to PD-L1, and a transmembrane domain or a fragment thereof. The disclosure also provides PD-1 Fc fusion proteins including an immunoglobulin Fc region, and a PD-1 polypeptide variant. | 2022-03-10 |
20220073587 | RECOMBINANT HUMAN 2IG-B7-H3 PROTEIN CODING GENE, RECOMBINANT VECTOR, HOST CELL COMPRISING THE SAME, PHARMACEUTICAL COMPOSITION AND USE THEREOF - The present disclosure relates to the field of genetic engineering, in particular to a recombinant human 2Ig-B7-H3 protein encoding gene, a protein, a recombinant vector, and a pharmaceutical composition including the gene or protein. The recombinant human 2Ig-B7-H3 protein encoding gene comprises a nucleotide sequence shown in SEQ ID NO:1. | 2022-03-10 |
20220073588 | TARGETED HETERODIMERIC Fc FUSION PROTEINS CONTAINING IL-15 IL-15alpha AND ANTIGEN BINDING DOMAINS - The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc fusion protein and an antigen binding domain Fc fusion proteins. In some instances, the antigen binding domain binds to CD8, NKG2A, or NKG2D. | 2022-03-10 |
20220073589 | GPR156 Variants And Uses Thereof - The disclosure provides nucleic acids, including cDNA, comprising alterations that encode aspartic acid at a position corresponding to position 533 of the human G protein-coupled receptor 156 protein (GPR156). The disclosure also provides isolated and recombinant human GPR156 protein variants that comprise an aspartic acid at a position corresponding to position 533. The change to aspartic acid, and the gene encoding this change, associate with unipolar depression. The disclosure also provides methods for determining whether a subject has or has a risk of developing unipolar depression, based on the identification of such alterations in the gene (DNA or RNA) encoding GPR156. | 2022-03-10 |
20220073590 | Fusion Albumin Nanoparticle and Application Thereof - The disclosure discloses a fusion albumin nanoparticle and application thereof, and belongs to the technical field of biomedicine. In the disclosure, fusion albumin is expressed by using a genetic engineering technology, and the fusion albumin nanoparticle is formed by performing self-assembly and drug loading on the fusion albumin in a neutral aqueous solution. The fusion albumin studied in the disclosure has targetability, pH and enzyme-sensitive functional groups, the nanoparticle prepared by using the fusion albumin has the functions of targetability and controlled drug release, and a method for preparing the fusion albumin nanoparticle is simple and easy to implement and has great application potential. | 2022-03-10 |
20220073591 | RECOMBINANT CLUSTERIN AND USE THEREOF IN THE TREATMENT AND PREVENTION OF DISEASE - Recombinant clusterin polypeptides and compositions comprising the same are provided. In some aspects, recombinant clusterin or nucleic acids encoding the same may be used for treating and preventing an abnormality of morphology and function in a mammal with disease (e.g., cardiovascular diseases or alcoholism). | 2022-03-10 |
20220073592 | SYNTHETIC AND RECOMBINANT COLLAGEN PEPTIDES HAVING BIOLOGICAL ACTIVITY - The present invention relates to a synthetically or recombinantly produced collagen peptide for use in a method for the therapeutic treatment of the human or animal body having a molecular weight in a range from 0.18 to 10.0 kDa, in particular 0.18 to 5.0 kDa, in particular 1.1 to 5.0 kDa, products which comprise a collagen peptide according to the invention, and a method for producing a collagen peptide according to the invention. | 2022-03-10 |
20220073593 | Modification of Antibody FcRn binding - Herein is reported a method for providing a modified antibody with improved in vivo half-live, comprising the modification of the Fc-region of the antibody by introducing one or more mutations that change the binding of the Fc-region to human FcRn until the (relative) retention time of the modified antibody in an FcRn affinity chromatography is increased for more than 1 minute but not more than 5 minutes compared to the parent antibody. | 2022-03-10 |
20220073594 | ANTI-SARS-COV-2 NEUTRALIZING ANTIBODIES - The present disclosure provides novel neutralizing antibodies against SARS-COV-2, and the antigen binding fragments thereof. Pharmaceutical composition and kits comprising the same, and the uses thereof are also provided. | 2022-03-10 |
20220073595 | ANTIBODY DIRECTED AGAINST S. AUREUS CLUMPING FACTOR A (ClfA) - The present disclosure is directed to a monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to a | 2022-03-10 |
20220073596 | METHOD FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS - The invention is in the field of methods and preparations for medical treatments, in particular the treatment of idiopathic pulmonary fibrosis (IPF). The invention provides such methods wherein antibodies or fragments thereof that react with selected citrullinated epitopes are used in the treatment of IPF. Antibodies against citrullinated epitopes situated at the amino terminus of hi stone polypeptides H2A and H4 were found to be particularly useful. The invention therefore relates to an antibody specifically reactive with a citrullinated epitope on the N-terminus of deiminated histone H2A or H4 for use in the prevention or treatment of idiopathic pulmonary fibrosis. | 2022-03-10 |
20220073597 | CHIMERIC ANTIGEN RECEPTOR EFFECTOR CELL SWITCHES WITH HUMANIZED TARGETING MOIETIES AND/OR OPTIMIZED CHIMERIC ANTIGEN RECEPTOR INTERACTING DOMAINS AND USES THEREOF - The present disclosure provides compositions, methods, kits, and platforms for selectively activating and deactivating chimeric receptor effector cells using humanized chimeric receptor effector cell switches that comprise a humanized targeting moiety that binds CD19 on a target cell and a chimeric receptor interacting domain that binds to a chimeric receptor effector cell and/or chimeric receptor effector cell switches comprising optimized chimeric receptor interacting domains. Also disclosed are methods of treating disease and conditions with such chimeric receptor effector cells and chimeric receptor effector cell switches. | 2022-03-10 |
20220073598 | ANTAGONISTS - The invention relates to Bone Morphogenetic Protein 6 (BMP6) antagonists, such as antibodies and fragments, as well as methods, uses and combinations. | 2022-03-10 |
20220073599 | ANTIBODY THAT BINDS TO VEGF-A AND ANG2 AND METHODS OF USE - The present invention relates to anti-VEGF-A/anti-ANG2 antibodies, e.g. in the form of a bispecific Fab fragment, and methods of using the same. | 2022-03-10 |
20220073600 | METHODS FOR TREATING DISEASE USING PSMP ANTAGONISTS - Disclosed are antagonists of PC3-secreted microprotein (PSMP) and use of the antagonists for treatment of liver, lung, or kidney fibrosis, including various diseases or disorders associated with liver, lung, or kidney fibrosis such as, e.g., non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), drug-induced lung injury, acute kidney injury (AKI), chronic kidney disease (CKD), lupus nephritis, IgA nephropathy, and membranous glomerulonephritis. Also disclosed are PSMP antagonists and their use for treatment of graft-versus-host disease (GVHD) and systemic lupus erythematosus (SLE). Suitable PSMP antagonists for use in disease treatment include PSMP-binding proteins such as, for example, neutralizing anti-PSMP antibodies. | 2022-03-10 |
20220073601 | USE OF ANTI-FAM19A5 ANTIBODIES FOR TREATING FIBROSIS - The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat or to diagnose a fibrosis and/or a fibrosis-associated disease in a subject in need thereof. | 2022-03-10 |
20220073602 | Antibodies with improved stability to intestinal digestion - The present invention provides for recombinant antibodies having the features of ruminant early colostrum antibodies that impart resistance to proteases and intestinal digestion. It is a feature of the present invention that when administered to animals including humans, pharmaceutical compositions comprising the novel recombinant antibodies of the present invention, advantageously exhibit resistance to proteases and intestinal digestion. Thus, pharmaceutical compositions of the recombinant antibodies of the invention may be used to deliver antibody therapeutics particularly by oral delivery to the gastrointestinal tract when oral delivery is advantageous. | 2022-03-10 |
20220073603 | Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody - Anti-IL-12/IL-23p40 antibodies, such as ustekinumab, are used in methods and compositions for safe and effective treatment of psoriasis, particularly moderate to severe chronic plaque psoriasis, in pediatric patients. The methods and compositions address a clear unmet medical need in this patient population. | 2022-03-10 |
20220073604 | IL-6 BINDING MOLECULES - The present invention provides binding molecules (e.g., antibodies or antigen binding fragments thereof) that specifically bind to and inhibit the biological activity of IL-6 (e.g., human, mouse and non-human primate IL-6). In a preferred embodiment, the antibodies or antigen binding fragments of the invention bind to IL-6 and inhibit its binding to an IL-6 receptor. Such antibodies or antigen binding fragments are particularly useful for treating IL-6-associated diseases or disorders (e.g., inflammatory disease and cancer). | 2022-03-10 |
20220073605 | CLAZAKIZUMAB IN THE TREATMENT OF CHRONIC ANTIBODY-MEDIATED REJECTION OF ORGAN TRANSPLANT - Described herein are methods for treating antibody mediated rejection (ABMR), especially chronic active ABMR (cABMR), of transplanted organs using clazakizumab Human kidney transplant recipients with biopsy-proven cABMR, transplant glomerulopathy and who are donor-specific antibody positive showed stabilization of renal function and lowered DSA levels following clazakizumab treatment. The estimated glomerular filtration rate of the patients at six, 12 or even 18 months were stabilized, inflammatory markers of cABMR were reduced or stabilized, and inflammatory blood markers were reduced, since clazakizumab treatment. | 2022-03-10 |
20220073606 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF - The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Embodiments of this invention relate to the binding fragments of antibodies described herein, comprising the sequences of the V | 2022-03-10 |
20220073607 | METHODS FOR EPITOPE SELECTION - The present invention relates to certain new methods to select epitopes for antibodies. The present invention also provides a method of generating an antibody (e.g. a functional antibody) to a protein, said method comprising (i) identifying an antigenic epitope in said protein by exposing the protein to limited or restricted proteolysis by contacting the protein with at least one protease to form at least one digested, deconstructed or truncated version of the protein and at least one surface-exposed peptide that is cleaved off from the protein by the action of said protease and generating an antigenic epitope based on said surface-exposed peptide; and (ii) raising an antibody against the antigenic epitope. The present invention also provides antigenic epitopes and antibodies against such epitopes. | 2022-03-10 |
20220073608 | SEMA4D ANTIBODY, PREPARATION METHOD THEREFOR AND USE THEREOF - Provided are a murine or fully human monoclonal antibody targeting SEMA4D and a preparation method therefor, wherein the antibody binds to the SEMA4D antigen and has activities such as combating tumors. | 2022-03-10 |
20220073609 | ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF - In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity. | 2022-03-10 |
20220073610 | BIVALENT BISPECIFIC ANTIBODY AND PREPARTION METHOD THEREOF, CODING GENE, HOST CELL AND COMPOSITION - Provided are a bivalent bispecific antibody and a preparation method thereof, a coding gene, a host cell and a composition. The bivalent bispecific antibody comprises: a) a single-chain variable fragment scFv, a flexible peptide, a heavy chain IgG1 constant region CH1 and a hinge region partial sequence of the antibody that specifically binds to a first antigen, and b) a single-chain variable fragment scFv, and a light chain constant region CL, that is, scFv1-CL or CL-scFv1, of the antibody that specifically binds to a second antigen; or comprises: c) a light chain and a heavy chain of the antibody that specifically binds to the first antigen, and d) a light chain and a heavy chain of the antibody that specifically binds to the second antigen. | 2022-03-10 |
20220073611 | ANTI-NMDA RECEPTOR ANTIBODIES AND METHODS OF USE - A recombinant, synthetic or monoclonal human antibody or fragment thereof that binds to an N-methyl-D-aspartate Receptor (NMDAR) epitope, which antibody or fragment comprises at least one a heavy chain variable domain sequence encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NOs. 1, 3, or 5; or at least one a light chain variable domain sequence encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NOs: 2, 4, or 6. Assays for diagnosis of ANRE employ these NMDAR-binding antibodies, constructs, or epitope binding fragments. In one embodiment, multiple of the NMDAR-binding antibodies or fragments are used as controls because they bind non-overlapping target sequences on the NMDAR ATD. | 2022-03-10 |
20220073612 | ANTIBODIES SPECIFIC TO DELTA 1 CHAIN OF T CELL RECEPTOR - Disclosed herein are antibodies specific to a delta-1 chain of a γδ T cell receptor and methods of using such for modulating γδ T cell bioactivity. Such anti-Delta 1 antibodies may also be used to treat diseases associated with γδ T cell activation, such as solid tumors, or for detecting presence of γδ1 T cells. | 2022-03-10 |
20220073613 | ACTIVATABLE MASKED ANTI-CTLA4 BINDING PROTEINS - The invention provides activatable masked anti-CTLA4 binding proteins (e.g., antibodies, bispecific antibodies, and chimeric receptors) and their use in treating and preventing cancer, as well as compositions and kits comprising the activatable masked anti-CTLA4 binding proteins. | 2022-03-10 |
20220073614 | DNA MONOCLONAL ANTIBODIES TARGETING PD-1 FOR THE TREATMENT AND PREVENTION OF CANCER - Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody or fragment thereof that targets programmed cell death protein 1 (PD-1). The disclosure also provides a method of preventing and/or treating disease, such as cancer, in a subject using the composition of the invention. | 2022-03-10 |
20220073615 | MIXTURES OF ANTIBODIES - Described herein are antibodies and mixtures of antibodies optionally produced by a host cell line, nucleic acids encoding the antibodies and mixtures of antibodies, host cells containing such nucleic acids, and methods of treatment using the antibodies, mixtures of antibodies, or nucleic acids encoding the antibodies or mixtures of antibodies. Also described are methods of producing mixtures of antibodies in host cells. | 2022-03-10 |
20220073616 | METHODS OF ADMINISTERING ANTI-TIM-3 ANTIBODIES - The invention is based, in part, upon the discovery of a family of antibodies that specifically bind human T Cell Immunoglobulin and Mucin Domain-3 (TIM-3). More specifically, this invention relates to a method of treating cancer by administering an anti-TIM-3 antibody in combination with an anti-PD-L1/TGFβ Trap fusion protein. When administered to a human cancer patient or an animal model, the antibodies inhibit or reduce tumor growth in the human patient or animal model. | 2022-03-10 |
20220073617 | Antibodies Binding to Vista at Acidic pH - The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH. | 2022-03-10 |
20220073618 | HUMANIZED ANTI-HUMAN PD-L1 MONOCLONAL ANTIBODY AND PREPARATION METHOD THEREFOR AND USE THEREOF - The present invention relates to a humanized anti-human PD-L1 monoclonal antibody, and a preparation method and use thereof. The humanized anti-human PD-L1 monoclonal antibody provided in the present invention has high affinity and specificity for PD-L1, stimulates T cells to secrete cytokines, and specifically relieves the negative immune regulation by PD-L1. The effect of this antibody is not achieved by directly blocking the interaction between PD-1 and PD-L1, presenting a new mechanism of immune checkpoint regulation. Therefore, the functional humanized anti-human PD-L1 monoclonal antibody provided in the present invention activates T cells by regulating the PD-L1 signaling pathway, thereby achieving the purpose of tumor immunotherapy. | 2022-03-10 |
20220073619 | BTN3A BINDING PROTEINS AND USES THEREOF - It is disclosed anti-BTN3A activating antibody fragments that specifically bind to BTN3A and activate the cytolytic function of Vγ9/Vδ2 T cells. The disclosure more specifically relates to specific anti-BTN3A binding proteins comprising such activating antibody fragments and their use in the manufacturing of novel drugs for use in treating cancer disorders, in particular cancers susceptible to be treated with activated γδ T cells. | 2022-03-10 |
20220073620 | ANTIBODY FUSION PROTEIN, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF - Provided are an antibody fusion protein, a preparation method thereof and an application thereof. The antibody fusion protein is high in expression quantity, and the transient expression quantity in mammalian cells 293E is 100-150 mg/L; the antibody fusion protein is high in assembly rate, and the correct assembly rate exceeds 95%; the antibody fusion protein has a high affinity, and a single-sided antibody/fusion protein and antigen binding KD value is equivalent to a positive control monoclonal antibody/fusion protein and antigen binding KD value; the antibody fusion protein is convenient to purify, and the purity can reach more than 95% in one-step purification by using Protein A or Protein L, and the tumor inhibition rate in a pharmacodynamic experiment animal can reach up to 92%. | 2022-03-10 |
20220073621 | ANTI-PD-L1 ANTIBODY AND USE THEREOF - The present application provides an anti-PD-L1 antibody, an antigen-binding fragment thereof, and use thereof. The present application also provides a multispecific antibody such as a bispecific antibody, a conjugate, and a composition comprising the anti-PD-L1 antibody or the antigen-binding fragment thereof, and use thereof in treatment of diseases such as cancer. | 2022-03-10 |
20220073622 | Compositions and Methods for Treating Late Stage Lung Cancer - Disclosed are methods for treating late stage (e.g., clinical stage III or IV), unresectable non-small-cell lung cancer (NSCLC) with an antibody that inhibits PD1/PD-L1 activity in a patient identified as having not progressed following definitive chemoradiation therapy. | 2022-03-10 |
20220073623 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER - The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, non-small cell lung cancer (NSCLC). The invention provides methods of treating NSCLC, methods of determining whether a patient suffering from NSCLC is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from NSCLC to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from NSCLC, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor cells and/or tumor-infiltrating immune cells). | 2022-03-10 |
20220073624 | FUSION PROTEINS TARGETING TUMOUR ASSOCIATED MACROPHAGES FOR TREATING CANCER - The present invention relates to cancer immunotherapy. In particular, provided herein are fusion proteins for targeting tumor associated macrophages with immunostimulatory agents. | 2022-03-10 |
20220073625 | HUMANIZED ANTI-AXL ANTIBODIES - The present disclosure relates to humanized anti-Axl antibodies. | 2022-03-10 |
20220073626 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR ENHANCING CD8+ T CELL-DEPENDENT IMMUNE RESPONSES IN SUBJECTS SUFFERING FROM CANCER - Targeting immune checkpoints, such as Programmed cell Death 1 (PD1), has improved survival in cancer patients by unleashing exhausted CD8+ T-cell thereby restoring anti-tumor immune responses. Most patients, however, relapse or are refractory to immune checkpoint blocking therapies. Here, the inventors show that NRP1 is recruited in the cytolytic synapse of PD1+CD8+ T-cells, interacts and enhances PD-1 activity. In mice, CD8+ T-cell specific deletion of Nrp1 improves spontaneous and anti PD1 antibody anti-tumor immune responses. Likewise, in human metastatic melanoma, the expression of NRP1 in tumor infiltrating CD8+ T-cells QI predicts poor outcome of patients treated with anti-PD1 (e.g. pembrolizumab). Finally, the combination of anti-NRP1 and anti-PD1 antibodies is synergistic in human, specifically in CD8+ T-cells anti-tumor response. Thus the therapeutic inhibition of NRP1 alone or combined with an immune checkpoint inhibitor (e.g. anti-PD1 antibody) could efficiently repress tumor growth in human cancer. The present invention also relates to multispecific antibodies comprising at least one binding site that specifically binds to an immune checkpoint molecule (e.g. PD-1), and at least one binding site that specifically binds to NRP-1. The present invention also relates to a population of cells engineered to express a chimeric antigen receptor (CAR) and wherein the expression of NRP-1 in said cells is repressed. | 2022-03-10 |
20220073627 | BINDING PROTEINS AND METHODS OF USE THEREOF - The present disclosure provides binding proteins, such as antibodies, that bind to a GDNF Family Receptor Alpha Like (GFRAL) protein, including human GFRAL protein, and methods of their use. | 2022-03-10 |
20220073628 | ANTI-IL-36R ANTIBODIES FOR THE TREATMENT OF NEUTROPHILIC DERMATOSES - The present invention provides methods for treating, preventing or ameliorating a neutrophilic dermatosis. The methods of the present invention include administering to a patient suffering from a neutrophilic dermatosis a pharmaceutical composition including an anti-interleukin-36 receptor (anit-IL-36R) antibody. | 2022-03-10 |
20220073629 | Humanized Anti-CXCR5 Antibodies, Derivatives Thereof and Their Uses - The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders. | 2022-03-10 |
20220073630 | A PEPTIDE-MHC-I-ANTIBODY FUSION PROTEIN FOR THERAPEUTIC USE IN A PATIENT WITH AMPLIFIED IMMUNE RESPONSE - The present invention relates to a peptide-MHC-I-antibody fusion protein for use as a therapeutic medicament administered to a patient, wherein a cellular cytotoxic immune response towards the virus-derived peptide has been amplified in the patient. The therapeutic medicament may be used in a kit of parts and administered in combination with an amplifying medicament and optionally an inducing medicament. The inducing medicament and the amplifying medicament may be for use in a method of making a patient susceptible for a treatment with the peptide-MHC-I-antibody fusion protein. The medicament(s) may be used for the treatment of diseases, such as cancer or a viral infection. | 2022-03-10 |
20220073631 | MONOCLONAL ANTIBODY AGAINST HUMAN INTERLEUKIN-4 RECEPTOR ALPHA AND USE THEREOF - Provided are antibodies and fragments against human interleukin-4 receptor alpha (hIL-4Rα) and uses thereof. The antibodies and fragments preferably have heavy chain complementary determining regions as set forth in SEQ ID NOs: 1-3 or 14-16 and light chain complementary determining regions as set forth in SEQ ID NOs: 4-6 or 17-19. | 2022-03-10 |
20220073632 | ANTIGEN-BINDING DOMAIN, AND POLYPEPTIDE INCLUDING CONVEYING SECTION - The present invention relates to a polypeptide comprising an antigen binding domain and a carrying moiety having an inhibiting domain that inhibits the antigen binding activity of the antigen binding domain, and having a longer half-life than that of the antigen binding domain existing alone, methods for producing and screening for the polypeptide, a pharmaceutical composition comprising the polypeptide, methods for producing and screening for a single-domain antibody whose antigen binding activity is inhibited by associating with particular VL, VH or VHH, and a fusion polypeptide library including a single-domain antibody whose antigen binding activity is inhibited by associating with particular VL, VH or VHH. | 2022-03-10 |
20220073633 | ANTI-MULLERIAN HORMONE RECEPTOR BINDING PEPTIDES - Disclosed are compositions and methods including Anti-Müllerian Hormone (AMH) receptor binding peptides. The AMH receptor binding peptides can be used, for example, to modify the activity of the AMH receptor. For example, the AMH receptor binding peptides can activate the AMH receptor, such as the AMH receptor 2, thereby mimicking the function of AMH. In other examples, the AMH receptor binding peptides function as AMH receptor antagonists, thereby interfering with the function of endogenous AMH. By modifying the activity of the AMH receptor, the peptides have multiple applications, including for example modification of treatment of precocious puberty in females, delay of natural menopause, preservation of ovarian follicular reserve, contraception, fertility preservation after ovarian cortex transplant, treatment of endometriosis, treatment of cancer and/or cancer prevention, and treatment of polycystic ovary syndrome (PCOS). | 2022-03-10 |
20220073634 | NOVEL AGONISTIC ANTI TNFR2 ANTIBODY MOLECULES - Described are novel antagonistic antibody molecules that specifically bind to TNFR2 on a target cell and thereby block TNF-α binding to TNFR2 and block TNFR2 signaling, wherein the antibody molecules also bind to Fc receptors via the Fc region. Also described is the use of such antibody molecules in treatment of cancer or infections caused by intracellular pathogens. | 2022-03-10 |
20220073635 | NOVEL POLYPEPTIDES - The invention provides bispecific polypeptides comprising a first binding domain, designated B1, which is capable of binding specifically to CD40, and a second binding domain, designated B2, which is capable of specifically binding to a tumour cell-associated antigen. Also provided are pharmaceutical compositions of such bispecific polypeptides and uses of the same in medicine. | 2022-03-10 |
20220073636 | ANTIBODY POLYPEPTIDES THAT ANTAGONIZE CD40L - Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single V | 2022-03-10 |
20220073637 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES - Provided herein are, inter alia, anti-CD6 antibody-growth factor complexes including an anti-CD6 antibody portion bound to a growth factor protein (e.g., EGF) through a linker, which may be cleavable by a protease (e.g., diabetic microenvironment specific protease). The compositions provided herein are, inter alia, useful for the treatment of autoimmune diseases (e.g., type I diabetes). | 2022-03-10 |
20220073638 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCERS RESISTANT TO IMMUNE CHECKPOINT THERAPY - Recent advances in the understanding of macrophage biology has revealed that tumor-associated macrophages are very heterogeneous and that several distinct subsets coexist in the tumor microenvironment. These subsets differ not only in terms of expression profile and origin but also in their pro- or anti-tumoral function. Here, the inventors describe a macrophage subset in mouse models of metastatic melanoma that express CD 163. Specific depletion of the CD 163 expressing cells in an anti-PD-1 checkpoint inhibitor resistant melanoma model using cytotoxic lipid nanoparticles conjugated to αCD163 mAh results in a massive infiltration of CD4+ and activated CD8 | 2022-03-10 |
20220073639 | Use of CD2/5/7 Knock-Out Anti-CD2/5/7 Chimeric Antigen Receptor T cells Against T Cell Lymphomas and Leukemias - The present invention includes compositions and methods for treating T cell lymphomas and leukemias. In certain aspects, the compositions and methods include CAR T cells targeting CD2, CD5, or CD7 and modified cells wherein CD2, CD5, or CD7 has been knocked-out. | 2022-03-10 |
20220073640 | CD133-BINDING AGENTS AND USES THEREOF - This disclosure is directed to novel CD133-binding agents. The disclosure is also directed to uses of novel CD133-binding agents for detecting CD133-expressing cells and/or quantitating levels of cellular CD133 expression, for targeting CD133-expressing cells, for decreasing levels of CD133 in CD133-expressing cells and for treating or preventing cancer. | 2022-03-10 |
20220073641 | FUSION PROTEIN OF ANTIBODY THAT RECOGNIZES CANCER CELLS AND MUTANT STREPTAVIDIN - It is an object of the present invention to provide a fusion protein of an antibody that recognizes cancer cells and a mutant streptavidin, which is for use in the treatment or diagnosis of cancer. According to the present invention, provided is a fusion protein having the amino acid sequence as set forth in SEQ ID NO: 2 or SEQ ID NO: 7, a linker sequence, and the amino acid sequence as set forth in SEQ ID NO: 1 (provided that the amino acid sequence portion consisting of 6 histidine residues at the C-terminus thereof may be partially or entirely deleted), from the N-terminal side to the C-terminal side, in this order. | 2022-03-10 |
20220073642 | METHODS OF USING SURUFATINIB IN TREATING ADVANCED PANCREATIC AND EXTRA-PANCREATIC NEUROENDOCRINE TUMORS - Disclosed herein are methods of using surufatinib in treating pancreatic and extra-pancreatic neuroendocrine tumors and advanced well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors; the methods disclosed comprise administering to the patient an effective amount of surufatinib or a pharmaceutically acceptable salt thereof. | 2022-03-10 |
20220073643 | CLAUDIN18.2 BINDING MOIETIES AND USES THEREOF - Described herein are binding moieties, such as antibodies, that specifically bind Claudin18.2, and chimeric antigen receptors comprising such binding moieties. Further provided are engineered immune cells (such as T cells) comprising anti-Claudin 18.2 chimeric antigen receptors. Also disclosed are methods of treating Claudin18.2-expressing tumor or cancers using the binding moieties, chimeric antigen receptors and engineered immune cells. | 2022-03-10 |
20220073644 | BISPECIFIC ANTIBODY EXHIBITING INCREASED ALTERNATIVE FVIII-COFACTOR-FUNCTION ACTIVITY - The present invention provides light chain amino acid substitutions that improve the FVIII cofactor function-substituting activity of ACE910 (Emicizumab), novel light chains showing FVIII cofactor function-substituting activity, and heavy chain amino acid substitutions that improve the FVIII cofactor function-substituting activity of novel light chain-containing bispecific antibodies. | 2022-03-10 |
20220073645 | PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTION AND/OR TREATMENT OF DISEASE THAT DEVELOPS OR PROGRESSES AS A RESULT OF DECREASE OR LOSS OF ACTIVITY OF BLOOD COAGULATION FACTOR VIII AND/OR ACTIVATED BLOOD COAGULATION FACTOR VIII - The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes blood coagulation factor IX and/or activated blood coagulation factor IX and blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, diseases that develop and/or progress due to a decrease or deficiency in the activity of blood coagulation factor VIII and/or activated blood coagulation factor VIII can be prevented and/or treated more effectively. | 2022-03-10 |
20220073646 | BISPECIFIC ANTIBODIES WITH TETRAVALENCY FOR A COSTIMULATORY TNF RECEPTOR - The invention relates to novel bispecific antigen binding molecules, comprising (a) four moieties capable of specific binding to a costimulatory TNF receptor family member, (b) at least one moiety capable of specific binding to a target cell antigen, and (c) a Fc domain composed of a first and second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same. | 2022-03-10 |
20220073647 | APPLICATION OF PCSK9 INHIBITORS IN THE PREPARATION OF DRUGS FOR THE TREATMENT OF INFLAMMATORY AND IMMUNE DISEASES - The invention belongs to the biopharmaceutical. It involves the role and mechanism of PCSK9 in inflammatory immune diseases, and the application of PCSK9 inhibitors to the preparation of drugs for the treatment of inflammatory immune diseases mediated by T cells. In particular, it involves the use of PCSK9 monoclonal antibody, PCSK9 interference RNA and PCSK9 small molecule inhibitors for treating psoriasis, atopic dermatitis, or urticaria. The invention uses psoriasis as an embodiment for the study of inflammatory and immune diseases. It is found that PCSK9 plays an important role in the treatment of inflammatory immune diseases. The PCSK9 monoclonal antibody, PCSK9 interference RNA, and PCSK9 small molecule inhibitor can be further developed for treating inflammatory immune-diseases, such as psoriasis with fewer adverse reactions, at low cost, and with good efficacy. | 2022-03-10 |
20220073648 | INFLUENZA VACCINES AND METHODS OF USE THEREOF - The disclosure relates to anti-idiotypic antibodies and related influenza virus vaccines. | 2022-03-10 |
20220073649 | MIXED BINDING DOMAINS - A binding domain or a multimer or a variant thereof which comprises a variable region encoded by a nucleic acid based on, derived or obtained from an animal phylogenetically distal from a human, which variable region is paired with a human variable region. | 2022-03-10 |
20220073650 | SUBSTANCES AND METHODS FOR THE USE IN PREVENTION AND/OR TREATMENT IN HUNTINGON'S DISEASE - Disclosed is an apheresis device including a solid carrier capable of being contacted with the blood or plasma flow, characterised in that the solid carrier includes one or several HTT-binding molecule (s) capable of adsorbing HTT or fragments thereof in a specific manner from plasma or blood or other HTT containing body fluids such as CSF. | 2022-03-10 |
20220073651 | METHOD FOR PRODUCING HYDROGELS - The present invention provides a method of producing a polymer hydrogel comprising the steps of: (1) preparing an aqueous solution of a water soluble polysaccharide derivative and a polycarboxylic acid; (2) optionally agitating the solution, for example, by stirring; (3) isolating a polysaccharide derivative/polycarboxylic acid composite from the solution; and (4) heating the polysaccharide derivative/polycarboxylic acid composite at a temperature of at least about 80° C., thereby cross-linking the polysaccharide with the polycarboxylic acid. The invention also provides polymer hydrogels produced by the methods of the invention. | 2022-03-10 |
20220073652 | Method for Producing Hydrogels Coupling High Elastic Modulus and Absorbance - The present invention provides crosslinked carboxymethylcellulose having high elastic modulus coupled with high absorbance capacity when swollen in simulated gastric fluid/water (1:8) and simulated intestinal fluids. The invention further provides methods of making the crosslinked carboxymethylcellulose, compositions comprising the crosslinked carboxymethylcellulose and methods of using the crosslinked carboxymethylcellulose, for example, for treating overweight or obesity or for enhancing glycemic control. | 2022-03-10 |
20220073653 | CUBIC CYCLODEXTRIN FRAMEWORK-RGD COMPOSITION AND PREPARATION METHOD THEREFOR - A cubic cyclodextrin framework-RGD composition (RGD-COF) and a preparation method therefor. Specifically, the cyclodextrin framework-RGD composition contains a cyclodextrin framework (COF) having a cubic structure and RGD, and can escape from phagocytosis and clearance of macrophages, enhance migration and adhesiveness to damaged blood vessels, and efficiently target and aggregate activated platelets at damaged blood vessel sites, having application prospects on targeted diagnosis and treatment of diseases associated with uncontrolled hemorrhage, atherosclerosis and cerebral apoplexy. By utilizing the advantage that a cyclodextrin-metal organic framework (CD-MOF) has controllable dimensions, a cubic cyclodextrin framework-RGD composition for nanoscale intravenous injection or microscale topically external use is provided. | 2022-03-10 |
20220073654 | METHOD FOR CLEANING A POLYMERISATION REACTOR - A polymerization reactor for producing aqueous polymer dispersions by radically initiated emulsion polymerization of one or more ethylenically unsaturated monomers in the presence of one or more protective colloids and/or emulsifiers, is cleaned by initially charging an aqueous mixture comprising one or more ethylenically unsaturated monomers, one or more protective colloids and/or emulsifiers, but no oxidation initiator, the proportion of ethylenically unsaturated monomers being 20 to 70% by weight of the aqueous mixture, heating the aqueous mixture to a temperature of 50° C. to 100° C. for 5 minutes to 3 hours, adding one or more initiators and optionally further starting materials, initiating polymerization, removing the aqueous polymer dispersion thus obtained from the polymerization reactor and post-treating the dispersion to remove wall deposits detached during the process. | 2022-03-10 |
20220073655 | Product By Integrated Process for Producing Propylene Polymers and Copolymers with Reduced Greenhouse Gas Emission - A product made by a substantially zero-carbon-emission (ZCE) process for making propylene polymers and copolymers including: converting alkanes to the olefin monomers ethylene, propylene, and butene or combinations thereof, using renewable electric power and scrubbing the stack gases from any fired heaters or boilers to remove carbon dioxide, in an oxidative-coupling of methane plant including the steps of passing alkanes through an ethylene plant while adding oxygen, passing a portion of the polymerization grade ethylene through a 2-butene plant, and passing the 2-butene stream and a portion of the polymerization grade ethylene stream through a propylene plant. The polymerization grade propylene is polymerized to produce isotactic homopolymer polypropylene, or ethylene-propylene random copolymer, or impact-grade polypropylene containing ethylene-propylene rubber. | 2022-03-10 |
20220073656 | MULTI- OR DUAL-HEADED COMPOSITIONS USEFUL FOR CHAIN SHUTTLING AND PROCESS TO PREPARE THE SAME - The present disclosure relates to a process for synthesizing a multi- or dual-headed composition by using an alpha,omega-diene and an organometallic compound in the presence of a catalyst precursor. The present disclosure further relates to use of the compositions, as well as the process to make the same, in olefin polymerization. | 2022-03-10 |
20220073657 | ISOPRENE-BASED POLYMER LATEX COMPOSITION - An isoprene-based polymer latex composition includes a chloroprene polymer latex (A) and an isoprene polymer latex (B), in which the chloroprene polymer has a z-average particle size of 180 nm or greater and smaller than 300 nm, and a tetrahydrofuran-insoluble fraction of 80 to 99% by mass; the chloroprene polymer latex (A) is (1) a copolymer latex of chloroprene (A-1) and 2,3-dichloro-1,3-butadiene (A-2-1), or (2) a copolymer latex of the above (A-1) and (A-2-1), and another monomer (A-2-2); and the copolymer is obtained by copolymerization in which the ratio of 2,3-dichloro-1,3-butadiene (A-2-1) is 5.0 to 30.0% by mass relative to the total amount of the monomer components chloroprene (A-1) and 2,3-dichloro-1,3-butadiene (A-2-1) of 100% by mass. The isoprene-based polymer latex composition's quality is maintained, and the properties after cross-linking of a molded product obtained by dipping a dipping former into the composition multiple times do not deteriorate. | 2022-03-10 |
20220073658 | TELECHELIC POLYOLEFINS AND PROCESSES FOR PREPARING THE SAME - The present disclosure relates to novel telechelic polyolefins of the formula (I) and processes for preparing the same. In at least one aspect, the telechelic polyolefins of the formula (I) comprise unsaturations at both termini. | 2022-03-10 |
20220073659 | 4-METHYL-1-PENTENE/alpha-OLEFIN COPOLYMER, COMPOSITION COMPRISING THE COPOLYMER AND 4-METHYL-1-PENTENE COPOLYMER COMPOSITION - The present invention provides a 4-methyl-1-pentene/α-olefin copolymer being excellent in lightness, stress absorption, stress relaxation, vibration damping properties, scratch resistance, abrasion resistance, toughness, mechanical properties and flexibility, having no stickiness during molding operation and being excellent in the balance among these properties; a composition comprising the polymer; and uses thereof. The 4-methyl-1-pentene/α-olefin copolymer (A) of the present invention satisfies specific requirements, and comprises 5 to 95 mol % of a structural unit (i) derived from 4-methyl-1-pentene, 5 to 95 mol % of a structural unit (ii) derived from at least one kind of α-olefin selected from α-olefins having 2 to 20 carbon atoms excluding 4-methyl-1-pentene and 0 to 10 mol % of a structural unit (iii) derived from a non-conjugated polyene, provided that the total of the structural units (i), (ii), and (iii) is 100 mol %. | 2022-03-10 |
20220073660 | POLYMER AND METHODS FOR MANUFACTURING IT - The invention relates to a polymer having a main chain which is obtained by free radical emulsion polymerisation of a monomer mixture, which comprises at least one optionally substituted styrene, at least one C1-C4 alkyl (meth) acrylate and at least one ethylenically unsaturated monomer. The monomer mixture is polymerised in a reaction mixture comprising a natural and/or synthetic polymeric stabilator. According to the invention the polymer main chain further comprises a reaction product of silica sol and an unsaturated organosilicon compound. The invention relates also to methods of making such polymer. | 2022-03-10 |
20220073661 | NOVEL POLYSTYRENE-BASED POLYAMPHOLYTE HAVING UPPER CRITICAL SOLUTION TEMPERATURE, AND APPLICATION FOR SAME - Provided is a novel polystyrene-based polyampholyte having upper critical solution temperature (UCST)-type thermoresponsiveness and a method for producing the same. When monomers having halogenated vinylbenzyl trialkyl ammonium and p-styrenesulfonate as main components are radically polymerized in an aqueous solvent, a polyampholyte having an upper critical solution temperature is produced by optimizing the mole ratio between cationic groups and anionic groups and the amount of a radical initiator and a chain transfer agent to be added to thereby control the copolymer composition and the molecular weight. | 2022-03-10 |
20220073662 | SULFONATED POLYMER - Copolymer compositions and methods of making copolymer compositions with enhanced stability in high temperature and high salinity environments. The copolymers include hydrophobic monomers and sulfonated monomers. The sulfonated monomers can include 2-acrylamido-2-methylpropane sulfonic acid and allyl sulfonate. The sulfonated monomers increase the stability of the polymers in harsh conditions, and in high temperature, high salinity environments. The sulfonated monomers also reduce or prevent the hydrolysis of acrylamide groups, and therefore enhance the stability of the copolymer. The copolymer compositions can be made with free radical polymerization and an initiation complex. | 2022-03-10 |
20220073663 | ELECTROACTIVE FLUOROPOLYMERS COMPRISING POLARIZABLE GROUPS - A copolymer including fluorinated units of formula (I): | 2022-03-10 |
20220073664 | COMPOSITION INCLUDING CURABLE FLUOROPOLYMER AND CURATIVE AND METHODS OF MAKING AND USING THEM - The composition includes a curable fluoropolymer having nitrogen-containing cure sites and a curative including an organo onium cation and an anion represented by Formula (I) or Formula (II). The composition is free of metal cations or has not more than 20 parts per million metal cations and free of silicon dioxide or has less than 0.5 percent by weight silicon dioxide, based on the total weight of the composition. In some cases, the composition consists of the curable fluoropolymer and the curative. Shaped articles including the composition, a fluoroelastomer prepared by curing the composition, a method of making a fluoroelastomer article, and a process for making the composition are also described. | 2022-03-10 |
20220073665 | RESIN COMPOSITION, METHOD FOR PRODUCING RESIN COMPOSITION, MOLDED ARTICLE, AND METHOD FOR PRODUCING MOLDED ARTICLE - Provided is a resin composition that can suppress yellowing even when used in a transparent molded article having a large thickness. The resin composition according to the present invention contains a vinylidene fluoride polymer as a main component, and further contains an alkyl quaternary ammonium sulfate. A percentage of irregular sequences in the vinylidene fluoride polymer is 4% or greater. | 2022-03-10 |
20220073666 | PROCESS FOR PRODUCING PEG ACRYLATE-HNBR COPOLYMER - The present invention relates to a process for producing PEG acrylate-HNBR copolymer which exhibits excellent processability by latex hydrogenation of PEG acrylate-NBR latex to afford PEG acrylate-HNBR latex and subsequent coagulation. | 2022-03-10 |
20220073667 | COMPOSITION HAVING EXCELLENT COATING PROPERTIES - The present invention relates to a composition containing a compound (A) represented by the following general formula (I) and a compound having two or more polymerizable functional groups (B) in a molecule (except for compound (A)), wherein a mass ratio ((A)/(B)) of the compound (A) to the compound having two or more polymerizable functional groups (B) in a multi-molecule is 30/70 to 50/50: | 2022-03-10 |
20220073668 | PULVERULENT MIXTURE OF PRECROSSLINKED NITRILE RUBBERS - What are provided are pulverulent mixtures based on specific nitrile rubbers and at least one separating agent, and also a process for producing vulcanizable mixtures and vulcanizates made from these pulverulent mixtures, and the resultant vulcanizates and their use, especially in tyre treads, where an improvement in wet skid resistance, dry grip and rolling resistance delivers is observed with simultaneously good mixing characteristics. | 2022-03-10 |
20220073669 | CURABLE RESIN COMPOSITION AND CURED OBJECT THEREOF - Provided is a curable resin composition with which a cured object with low water absorbency and good impact resistance and heat resistance can be formed and which is preferably usable in three-dimensional shaping. The curable resin composition contains: a polyfunctional urethane (meth)acrylate (A); a hydrophilic monofunctional radical-polymerizable compound (B); a hydrophobic monofunctional radical-polymerizable compound (C); rubber particles (D); and a radical polymerization initiator (E), and the content of the rubber particles (D) is 8 parts by mass or more and 50 parts by mass or less with respect to 100 parts by mass of radical-polymerizable compounds. | 2022-03-10 |
20220073670 | UREA GROUP CONTAINING RHEOLOGY CONTROL ADDITIVE - The invention relates to a composition comprising: a) 10 to 60% by weight of one or more urea components having a number average molecular weight Mn above 350 g/mol, and b) 40 to 90% by weight of one or more carboxylic acid components according to formula (I): HO—R | 2022-03-10 |
20220073671 | Curable Composition - The present application may provide a curable composition capable of securing a waiting time after curing starts, efficiently controlling the relevant waiting time according to the application, and also controlling a curing rate after the waiting time to suit the application. A cured product of the curable composition may be included in a battery module, a battery pack or an automobile. | 2022-03-10 |
20220073672 | CURABLE COMPOUND, CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURABLE COMPOSITION - Provided is a curable composition including a urethanization reaction product of: a branched polyolefin diol; at least one selected from an isocyanurate product, an adduct product, and a biuret product, of an aliphatic diisocyanate having 6 to 10 total carbon atoms; and a hydroxy saturated C | 2022-03-10 |
20220073673 | POLYCARBONATE DIOL AND POLYURETHANE USING SAME - The present invention relates to a polycarbonate diol comprising a structural unit derived from a compound represented by the following formula (A) and a structural unit derived from a compound represented by the following formula (B), wherein the hydroxyl value is from 20 to 450 mg-KOH/g: | 2022-03-10 |
20220073674 | POLYURETHANE ELASTOMERS, BIO-ADDITIVE COMPOSITIONS - A polyurethane elastomer, which can be a foam, generated from (a) an organic diisocyanate, (b) a polyester resin, (c) a chain extender comprised of a polyhydric alcohol, (d) a crosslinker, (e) a plasticizer, (f) a surfactant, (g) a bio-additive, (h) a blowing agent, and (i) an optional dye; and optionally where the elastomer has, for example, a hardness value of, for example, from about 15 Asker C to about 60 Asker C, a tensile strength of from about 1 MPa to about 10 MPa, a resilience of from about 30 percent to about 60 percent, an elongation at break of from about 150 percent to about 700 percent, and a tear strength from about 2 Newtons/millimeters to about 4 Newtons/millimeters, and which elastomers can be selected for footwear. | 2022-03-10 |
20220073675 | DEGRADABLE POLYMER STRUCTURES FROM CARBON DIOXIDE AND OLEFIN AND CORRESPONDING METHOD - A method of producing a degradable material includes steps of providing δ-valerolactone 2-ethylidene-6-hepten-5-olide (EVL) or other suitable monomer; combining the EVL or other suitable monomer with a catalyst to form a reaction mixture; and subjecting the reaction mixture to conditions that will allow the EVL or other suitable monomer to react in the presence of the catalyst to thereby form a product composition including a polymer of the EVL or other suitable monomer, where the polymer is hydrolytically degradable. | 2022-03-10 |
20220073676 | COPOLYESTER FROM TEREPHTHALIC ACID CONTAINING LOW DIETHYLENE GLYCOL - Copolyesters made from the direct esterification of terephthalic acid with diols including ethylene glycol, but which contain low diethylene glycol (DEG) content, and processes for making the copolyesters. The copolyesters are characterized by comprising 1.0 wt % or less of DEG without requiring the use of DEG-suppressing additives. The processes are characterized by features including operating at lower pressures and lower EG:TPA feed mole ratios in the first esterification zone, while simultaneously at higher temperatures than typical operation in order to lower incorporation of DEG into the final polymer. | 2022-03-10 |
20220073677 | WATER DISPERSIBLE POLYMER FOR USE IN ADDITIVE MANUFACTURING - A water dispersible sulfopolymer for use as a material in the layer-wise additive manufacture of a 3D part made of a non water dispersible polymer wherein the water dispersible polymer is a reaction product of a metal sulfo monomer, the water dispersible sulfo-polymer being dispersible in water resulting in separation of the water dispersible polymer from the 3D part made of the non water dispersible polymer. | 2022-03-10 |
20220073678 | (POLY)ALKYLENE GLYCOL-CONTAINING COMPOUND - The present invention provides a (poly)alkylene glycol-containing compound having higher detergency for composite stains of hydrophilic stains and hydrophobic stains than conventional (poly)alkylene glycol-containing compounds. The present invention relates to a (poly)alkylene glycol-containing compound including: a hydrophobic structural moiety (A); a (poly)alkylene glycol moiety (B); and one lactam ring-containing structural unit (C), in its structure, the hydrophobic structural moiety (A) being present in a proportion of 2.5 to 60% by mass in 100% by mass of the (poly)alkylene glycol-containing compound. | 2022-03-10 |
20220073679 | RESIN COMPOSITION, MOLDED PRODUCT, METHOD FOR PRODUCING MOLDED PRODUCT, AND ANTIOXIDANT - To provide a polyamide resin composition preventing mold fouling during molding and capable of producing a molded product with an excellent color tone, as well as a molded product, a method for producing a molded product, and an antioxidant. The composition is a resin composition containing: a polyamide resin constituted of diamine-derived constituent units and dicarboxylic acid-derived constituent units, 70 mol % or more of the diamine-derived constituent units being derived from a compound represented by Formula (1), and 70 mol % or more of the dicarboxylic acid-derived constituent units being derived from an α,ω-linear aliphatic dicarboxylic acid having from 8 to 12 carbon atoms; and a compound represented by Formula (1), where R | 2022-03-10 |
20220073680 | POLYMER RESIN COMPOSITION, AND POLYMER FILM, RESIN LAMINATE USING THE SAME - The present disclosure relates to a polymer resin composition including a polyamide resin in which an average particle size of individual crystals measured by a small-angle X-ray scattering apparatus is reduced through an alternating segment structure, and at least one selected from the group consisting of a metal salt compound and an end-capping agent compound, and a polymer film and a resin laminate using the same. | 2022-03-10 |
20220073681 | Polyimide Precursor, Polyimide Precursor Composition, Polyimide Film, Manufacturing Method Thereof, and Use Thereof - The present invention relates to a polyimide precursor, a polyimide precursor solution, a polyimide film, a manufacturing method thereof, and a use thereof. The polyimide precursor according to the present invention may provide a polyimide film that has excellent heat resistance and satisfies transparency and a low coefficient of linear thermal expansion, and thus the polyimide film will be usefully applicable in the field of flexible displays requiring high dimensional stability. | 2022-03-10 |